JP2021527137A5 - - Google Patents
Info
- Publication number
- JP2021527137A5 JP2021527137A5 JP2021518994A JP2021518994A JP2021527137A5 JP 2021527137 A5 JP2021527137 A5 JP 2021527137A5 JP 2021518994 A JP2021518994 A JP 2021518994A JP 2021518994 A JP2021518994 A JP 2021518994A JP 2021527137 A5 JP2021527137 A5 JP 2021527137A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- rpn11
- nhme
- sme
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684265P | 2018-06-13 | 2018-06-13 | |
| US62/684,265 | 2018-06-13 | ||
| US201962835953P | 2019-04-18 | 2019-04-18 | |
| US62/835,953 | 2019-04-18 | ||
| PCT/EP2019/065481 WO2019238817A1 (en) | 2018-06-13 | 2019-06-13 | Bifunctional molecules for targeting rpn11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527137A JP2021527137A (ja) | 2021-10-11 |
| JP2021527137A5 true JP2021527137A5 (enExample) | 2022-06-21 |
Family
ID=67105990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518994A Pending JP2021527137A (ja) | 2018-06-13 | 2019-06-13 | Ｒｐｎ１１を標的化するための二機能性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11925690B2 (enExample) |
| EP (1) | EP3807272A1 (enExample) |
| JP (1) | JP2021527137A (enExample) |
| KR (1) | KR20210021016A (enExample) |
| CN (1) | CN112533918A (enExample) |
| CA (1) | CA3103185A1 (enExample) |
| WO (1) | WO2019238817A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240545A1 (es) | 2020-12-18 | 2024-03-19 | Amphista Therapeutics Ltd | Moleculas bifuncionales novedosas para la degradacion de proteinas dirigidas |
| MX2024004525A (es) * | 2021-10-14 | 2024-05-24 | Cullgen Shanghai Inc | Proteinas modificadas y degradadores de proteinas. |
| CN114959036A (zh) * | 2022-06-07 | 2022-08-30 | 北京大学 | Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用 |
| WO2023242598A1 (en) | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
| JP2025525347A (ja) | 2022-06-16 | 2025-08-05 | アンフィスタ セラピューティクス リミテッド | 標的タンパク質分解のための新規の二官能性分子 |
| CA3267147A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | COMPOUNDS FOR THE TARGETED DEGRADATION OF A PROTEIN |
| IL319486A (en) | 2022-10-07 | 2025-05-01 | Pfizer | HSD17B13 Inhibitors and/or Retarders |
| JP2025541231A (ja) | 2022-12-16 | 2025-12-18 | ファイザー・インク | ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用 |
| US20250188030A1 (en) | 2023-12-07 | 2025-06-12 | Pfizer Inc. | Biphenyl and Phenylpyridine Compounds |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2026088071A1 (en) | 2024-10-23 | 2026-04-30 | Pfizer Inc. | Substituted fused heteroaryl lactam compounds |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| WO1993020094A1 (en) | 1992-03-27 | 1993-10-14 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for quinoline |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| NZ513639A (en) * | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| EP1322750A4 (en) * | 2000-09-08 | 2004-09-29 | California Inst Of Techn | PROTEOLYSIS TARGET DRUG TARGET MEDICINE |
| US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
| JP5466507B2 (ja) | 2007-09-27 | 2014-04-09 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2012158435A1 (en) | 2011-05-17 | 2012-11-22 | Han-Jie Zhou | Compositions and methods for jamm protein inhibition |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US9913834B2 (en) | 2013-05-08 | 2018-03-13 | The Johns Hopkins University | Bis-benzylidine piperidone proteasome inhibitor with anticancer activity |
| CN119591582A (zh) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| KR20240119196A (ko) * | 2015-06-04 | 2024-08-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드계 조절인자 및 관련된 이용 방법 |
| KR20180021080A (ko) | 2015-06-19 | 2018-02-28 | 에츠코 미야모토 | 단백질 분해 유도 태그 및 그 용도 |
| AU2016301196B2 (en) | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US10005735B2 (en) * | 2015-08-17 | 2018-06-26 | California Institute Of Technology | Inhibitors of RPN11 |
| GB201516243D0 (en) * | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA3020792A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| AU2017361155B2 (en) | 2016-11-15 | 2023-03-30 | Tokyo University Of Science Foundation | Ras protein degradation inducing molecule and pharmaceutical composition |
| EP3746135A4 (en) | 2018-01-30 | 2022-03-09 | Foghorn Therapeutics Inc. | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE |
| CA3090414A1 (en) | 2018-02-23 | 2019-08-29 | Lei Wu | Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof |
| CA3090417A1 (en) | 2018-02-23 | 2019-08-29 | Dana-Farber Cancer Institute, Inc. | Small molecules for inducing selective protein degradation and uses thereof |
| EP3774772A1 (en) | 2018-04-13 | 2021-02-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3677693A1 (en) | 2019-01-03 | 2020-07-08 | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO | Transpochimeric gene trancripts (tcgts) as cancer biomarkers |
| AU2020205665C1 (en) | 2019-01-09 | 2025-10-02 | Dana-Farber Cancer Institute, Inc. | DOT1L degraders and uses thereof |
-
2019
- 2019-06-13 CN CN201980039241.8A patent/CN112533918A/zh not_active Withdrawn
- 2019-06-13 US US17/251,615 patent/US11925690B2/en active Active
- 2019-06-13 WO PCT/EP2019/065481 patent/WO2019238817A1/en not_active Ceased
- 2019-06-13 JP JP2021518994A patent/JP2021527137A/ja active Pending
- 2019-06-13 CA CA3103185A patent/CA3103185A1/en active Pending
- 2019-06-13 KR KR1020217000928A patent/KR20210021016A/ko not_active Withdrawn
- 2019-06-13 EP EP19733978.1A patent/EP3807272A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533181A5 (enExample) | ||
| CN101657454B (zh) | 18f-标记的叶酸类 | |
| JP7449864B2 (ja) | エバンスブルー誘導体の化学結合体ならびに前立腺癌を標的とするための放射線療法および造影剤としてのその使用 | |
| JP2011518194A5 (enExample) | ||
| Jacobson et al. | Rapid and simple one-step F-18 labeling of peptides | |
| US11401376B2 (en) | Chemical compounds for coating of nanostructures | |
| JP2022537773A5 (enExample) | ||
| RS56171B1 (sr) | Derivati stirilpiridina i njihova upotreba za vezivanje i imidžing amiloidnih plakova | |
| RS55855B1 (sr) | Derivati piridina i pirazina za tretman hronične opstruktivne bolesti pluća | |
| Gai et al. | Synthesis and evaluation of new bifunctional chelators with phosphonic acid arms for gallium-68 based PET imaging in melanoma | |
| KR20160074683A (ko) | 18ｆ-표지된 폴레이트 | |
| JP2007511494A5 (enExample) | ||
| CN102802672B (zh) | 髓鞘碱性蛋白的成像 | |
| US20230348378A1 (en) | Small molecule albumin binders | |
| CN117836013A (zh) | 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂 | |
| JP2014501714A (ja) | コンジュゲートおよび分子イメージングにおけるそれらの用途 | |
| JP5693950B2 (ja) | １８ｆ標識葉酸 | |
| US20040053911A1 (en) | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | |
| AU2014205481A1 (en) | Therapeutic indications of kinase inhibitors | |
| CN102558091B (zh) | 一种苯并噻唑类衍生物及其用途 | |
| Basuli et al. | A first synthesis of 18F‐radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity | |
| KR100186799B1 (ko) | 단백질에 금속 이온을 부착하기 위한 킬레이트제 | |
| Kimura et al. | Radiosynthesis of novel pitavastatin derivative ([18F] PTV‐F1) as a tracer for hepatic OATP using a one‐pot synthetic procedure | |
| Wang et al. | Rational design of pyridinium styryl derivatives as PET tracers for cardiac amyloidosis imaging | |
| Kogler et al. | Synthesis and preclinical evaluation of FAP-targeting radiotracers for PET and optical imaging |